Impact of curcumin in Non-alcoholic fatty liver disease

Phase 1

• Conditions: Condition 1: Nonalcoholic fatty liver disease (NAFLD). Condition 2: Other specified inflammatory liver diseases.; Fatty (change of) liver, not elsewhere classified; Other specified inflammatory liver diseases

• Registration Number: IRCT201702209662N12
• Lead Sponsor: Vice chancellor for research of Isfahan Cardiovascular Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Adult subjects with symptoms of metabolic syndrome including waist circumference greater than 102 cm (male) or greater than 88cm (female); blood pressure greater than or equal 130/ 85 mmHg; triglycerides greater than 150 mg/dl; high-density lipoprotein cholesterol (HDL-C) less than 40 mg/d (males) or less than 50 mg/d (females); and fasting blood glucose greater than 100 mg/dL were screened for eligibility. Also inclusion criteria were diagnosis of NAFLD (grades 1–3) according to liver ultrasonography.

Exclusion criteria: will be pregnancy or breastfeeding; NAFLD secondary to alcohol consumption; smoking, consumption of hypoglycemic; hypolipidemic; and anti-inflammatory medications as well as any drug known to affect hepatic function; and the presence of hepatitis; coronary; renal; pulmonary; and thyroid diseases

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified